logo
  

Nevada Regulators Launch Investigation Into Three Marijuana Dispensaries

Nevada regulators have launched an investigation into three marijuana dispensaries in the state for selling tainted cannabis flower.

The Nevada Cannabis Compliance Board or CCB said it has opened investigations into three marijuana dispensaries for selling the product that twice failed microbial testing.

In early March, the Department of Taxation and CCB directed all dispensaries and retail stores in Nevada to immediately stop selling Cherry OG F3, which failed laboratory testing for yeast and mold, coliforms, Enterobacteriaceae and Aspergillus.

At that time, the CCB had instructed dispensaries and retail stores to destroy or return the affected product to the cultivator and to inform that they have complied with the directive.

Despite the CCB's directive, three dispensaries in the state allegedly retained their inventory of Cherry OG and resumed selling the product in May. These dispensaries sold about 375 grams of the tainted flower between May 19, 2020 and June 29, 2020.

The three dispensaries are Waveseer of Las Vegas, LLC (Jenny's Dispensary); Paradise Wellness Center LLC (Las Vegas ReLeaf), and Desert Aire Wellness, LLC (Sahara Wellness).

The CCB noted that in mid-May, a hold on the product was temporarily lifted due to an error by the CCB that occurred during an unrelated investigation. However, the CCB's health and safety advisory remained in effect and dispensaries should not have retained the product in their inventory, under the directive.

The CCB advised consumers who have purchased the product to avoid consuming it, but added it has not received any reports of illness.

In December 2019, Nevada state officials issued a public health and safety notice, warning consumers and patients in the state to avoid consuming marijuana products that failed microbial testing. The products were sold by six retail stores and marijuana dispensaries.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Drug major Pfizer Inc. reported Tuesday higher earnings in its fourth quarter, above market estimates, and an all-time high revenues in its fiscal 2022. Meanwhile, the company projects sharply lower adjusted earnings and revenues in its fiscal 2023, below Wall Street estimates, reflecting projected decline for COVID-19 products. In pre-market activity on the NYSE, Pfizer shares were losing around Oil major Exxon Mobil Corp. (XOM) reported Tuesday that fourth-quarter net income was $12.75 billion or $3.09 per share, up from $8.87 million or $2.08 per share in the prior-year quarter. Excluding special items, adjusted earnings were $3.40 per share, compared to $2.05 per share in the prior-year... La Mirada, California-based Daiso California LLC is recalling certain Matsunaga Mini Shiruko Sand Biscuits citing undeclared soy, an allergen, the U.S. Food and Drug Administration said. The recall incolves Matsunaga Mini Shiruko Sand Biscuits with sku 4902773016966, packaged in four pink and cream bags chained together. Each individual serving is 25g for an entire product weight of 100g.
Follow RTT